Advances in nanoparticle mediated targeting of RNA binding protein for cancer

• Published in: Advanced drug delivery reviews Vol. 185; p. 114257
• Main Authors: Kashikar, Rama, Kotha, Arun K., Shah, Saurabh, Famta, Paras, Singh, Shashi Bala, Srivastava, Saurabh, Chougule, Mahavir Bhupal
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.06.2022
• Subjects: Cancer; Drug and gene delivery; Nanoparticle; RNA binding protein; NP; FDA; BBB; RNA; Nanoparticle; CELF2; DTX; CDK; IFN; UTR; ZFP36; GBM; PDI; MYC; RT-PCR; IGF2BP1; SPION; DOPE; RBP; DSPE; VEGF; RNA binding protein; ATRX; HCC; IGF; BCL; DTX-M; TARBP2; CDDP; PEG; PLGA; PD; AU; PRC1; PEI; DNA; CSDE1; SKN; DOTAP; CIRP; SNALP; HLA; Drug and gene delivery; TEM; CPI; PCR; Cancer
• ISSN: 0169-409X; 1872-8294
• DOI: 10.1016/j.addr.2022.114257

[Display omitted] RNA binding proteins (RBPs) enact a very crucial part in the RNA directive processes. Atypical expression of these RBPs affects many steps of RNA metabolism, majorly altering its expression. Altered expression and dysfunction of RNA binding proteins lead to cancer progression and other diseases. We enumerate various available interventions, and recent findings focused on targeting RBPs for cancer therapy and diagnosis. The treatment, sensitization, chemoprevention, gene-mediated, and virus mediated interventions were studied to treat and diagnose cancer. The application of passively and actively targeted lipidic nanoparticles, polymeric nanoparticles, virus-based particles, and vaccine-based immunotherapy for the delivery of therapeutic agent/s against cancer are discussed. We also discuss the formulation aspect of nanoparticles for achieving delivery at the site of action and ongoing clinical trials targeting RBPs.